All In MedTech

FDA Clearance Tracker · P240036

OmniaSecure™ MRI SureScan™ Lead Model 3930M

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this decision)Source: openFDAMethods & limitations

PMABreakthrough

Decided

Apr 22, 2025

Approved

Time to decision

186 days

Received Oct 18, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240036
Device name
OmniaSecure™ MRI SureScan™ Lead Model 3930M
Applicant location
Mounds View, MN
Received
Oct 18, 2024
Decided
Apr 22, 2025
Decision
Approved
Supplements
7 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NVY

FDA's approval statement

As written in FDA's record.

The Model 3930M lead is intended for single use in the right ventricle for pacing, sensing, cardioversion, and defibrillation when a cardiac implantable electronic device is indicated to treat patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias.This includes adolescent pediatric patients who are at least 30 kg and are also at least 12 years of age, and whose cardiac anatomy is conducive to RV coil placement.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NVY. The earliest in FDA's data is P920015, decided Dec 9, 1993.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.